Histone Deacetylase Inhibitor Entinostat Exerts Anti-NSCLC Effects Through the EGFR Signaling Pathway and MDM2-p53 Axis
Entinostat demonstrates strong anti-NSCLC activity by suppressing EGFR expression and downstream signaling, highlighting its potential as a therapeutic agent.
Authors
- Aoxuan Zhang
- Mingdong Li (ORCID: https://orcid.org/0000-0002-0262-1076)
- Siyu Zhou (ORCID: https://orcid.org/0000-0001-7459-9982)
- Sinian He
- Jiayi Li (ORCID: https://orcid.org/0000-0001-9647-2931)
- Yuqing Qian (ORCID: https://orcid.org/0009-0004-7460-4947)
- C Sui
- Ni Zhang (ORCID: https://orcid.org/0009-0005-0130-2240)
Institutions
- Jiangxi University of Traditional Chinese Medicine (CN)
- Chongqing University (CN)
Publication Details
- Journal
- Current Pharmaceutical Biotechnology
- Published
- 2026-01-05
- DOI
- https://doi.org/10.2174/0113892010415089251129072250
- Primary Topic
- Histone Deacetylase Inhibitors Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00